摘要
目的系统性评价心肌桥合并冠状动脉硬化发病的主要危险因素。方法计算机检索知网、万方、维普、生物医学及PubMed、Embase、Cochrane Library数据库相关研究,时间从建库截至2022年9月。两名研究员独立进行文献筛选并提取文献资料,并采用NOS评分系统对纳入研究质量进行评价,统计分析采用RevMan5.4软件。结果检索共获得917篇文献,最终纳入11篇文献,包含3052例患者,其中硬化组1782例,非硬化组1270例。文献NOS评分均≥7分,文献质量较高。各因素与心肌桥合并冠状动脉硬化合并的OR值(95%CI)为:年龄1.14(1.09~1.19)、吸烟1.03(1.02~1.04)、高血压1.91(1.46~2.51)、糖尿病1.59(1.00~2.55)、LDL-C 1.50(0.87~2.60)、CRP 1.18(0.85~1.64)、压缩程度1.14(1.08~1.20)、心肌桥厚度2.43(0.55~10.67)。结论早期识别危险因素及做出干预能为预防心血管疾病的发生及健康调护起到重大作用。
Objective To systematically evaluate the main risk factors of myocardial bridge complicated with coronary atherosclerosis.Methods Case-control studies related to PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure(CNKI),Wanfang Data Knowledge Service Platform,VIP and CBM Databases were searched by computer from the establishment of the database to September 2022.Two researchers independently screened and extracted literatures,and the quality of the included studies was evaluated by NOS scoring system.Revman5.4 software was used for statistical analysis.Results A total of 917 articles were retrieved,and 11 articles were finally included,including 3052 patients,including 1782 patients in the sclerosing group and 1270 patients in the non-sclerosing group.The NOS scores of the literature were all≥7,indicating high quality of the literature.The OR value(95%CI)of each factor and myocardial bridge combined with coronary artery stiffness was:age 1.14(1.09,1.19),smoking 1.03(1.02-1.04),hypertension 1.91(1.46-2.51),diabetes 1.59(1.00-2.55),LDL-C 1.50(0.87-2.60),CRP 1.18(0.85-1.64),compression degree 1.14(1.08-1.20),the MB thickness was 2.43(0.55-10.67).Conclusion Early identification of risk factors and intervention can prevent the occurrence of cardiovascular diseases and health care plays an important role.
作者
涂光
黄小密
曾艳芳
王能
童随阳
钱进
TU Guang;HUANG xiaomi;ZENG yanfang;WANG Neng;TONG Suiyang;QIAN Jin(Department of Cardiovascular Medicine,Suizhou Hospital,Hubei Medicine University,Suizhou,Hubei 441300,China)
出处
《重庆医学》
CAS
2023年第S01期137-141,共5页
Chongqing medicine
基金
湖北省自然科学基金(2020CFB179)
湖北省卫生健康委员会指导性项目(WJ2019F133)。